Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 9/20 | 1.00 |
| ▸ | ADRA2B | P18089 | 8/20 | 1.00 |
| ▸ | ADRA2C | P18825 | 8/20 | 1.00 |
| ▸ | HTR1D | P28221 | 4/20 | 1.00 |
| ▸ | CYP2D6 | P10635 | 3/20 | 1.00 |
| ▸ | NISCH | Q9Y2I1 | 3/20 | 1.00 |
| ▸ | HTR1B | P28222 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 5/20 | 0.97 |
| ▸ | BLM | P54132 | 3/20 | 0.97 |
| ▸ | ADRA1A | P35348 | 4/20 | 0.71 |
| ▸ | ADRA1D | P25100 | 3/20 | 0.71 |
| ▸ | ADRA1B | P35368 | 3/20 | 0.71 |
| ▸ | TSHR | P16473 | 2/20 | 0.71 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.71 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.71 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.66 |
| ▸ | HRH2 | P25021 | 2/20 | 0.66 |
| ▸ | MEN1 | O00255 | 1/20 | 0.66 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Pi-Clonidine SCHEMBL5274141 | 0.98 | LMNA (1.00) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| SCHEMBL11180812 | 0.86 | ADRA2A (0.76) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| Apraclonidine SCHEMBL34128 | 0.83 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| SCHEMBL10414088 | 0.83 | ADRA2A (0.71) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| SCHEMBL11761437 | 0.83 | ADRA2C (0.71) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| Bromide SCHEMBL11608848 | 0.82 | ADRA2A (0.69) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| Apraclonidine SCHEMBL1649431 | 0.82 | ADRA2A (0.97) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| Apraclonidine SCHEMBL1002875 | 0.82 | BLM (1.00) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| Clonidine SCHEMBL5983 | 0.79 | ADRA2A (1.00) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 | |
| SCHEMBL564328 | 0.78 | CYP2D6 (0.68) | ADRA2AADRA2BADRA2CHTR1DCYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030224429-A1 | DNA sequence encoding a human imidazoline receptor and method for cloning the same | THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER | 2003-12-04 | — | — | US | claimed |
| US-6576742-B1 | Isolated polypeptide of given amino acid sequence; binds to moxonidine or p-iodoclonidine; use in screening for drugs having greater potency and/or more selectivity | THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER | 2003-06-10 | — | — | US | claimed |
| US-6391871-B1 | PENETRATING BLOOD BRAIN BARRIER | OLNEY JOHN W (US) | 2002-05-21 | — | — | US | claimed |
| WO-2000061144-A1 | METHOD AND MEANS FOR PREVENTING, TREATING, AND DIAGNOSING CARDIOVASCULAR COMPLICATIONS IN PATIENTS WITH OBSTRUCTIVE SLEEP APNEA | HEDNER JAN (SE) | 2000-10-19 | — | — | WO | claimed |
| US-6066675-A | Method for treatment of retinal diseases | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2000-05-23 | — | — | US | claimed |
| WO-1997031945-A1 | DNA ENCODING A HUMAN IMIDAZOLINE RECEPTOR | THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER (US) | 1997-09-04 | — | — | WO | claimed |
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS INC (US) | 2025-06-05 | — | — | US | disclosed |
| CN-119497589-A | Therapeutic combinations, compositions and methods for designing and producing conditions that promote mental well-being | 心境设计实验室股份有限公司 | 2025-02-21 | — | — | CN | disclosed |
| WO-2023172701-A2 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | MINDSTATE DESIGN LABS, INC. (US) | 2023-09-14 | — | — | WO | disclosed |
| WO-2016105448-A1 | IMIDAZOLINE RECEPTOR TYPE 1 LIGANDS FOR USE AS THERAPEUTICS | RIDEOUT DARRYL (US) | 2016-06-30 | — | — | WO | disclosed |
| WO-2016105449-A1 | COMPOUNDS FOR USE AS PAIN THERAPEUTICS | LEDERMAN SETH (US) | 2016-06-30 | — | — | WO | disclosed |
| US-8846674-B2 | Nitric oxide enhancing prostaglandin compounds, compositions and methods of use | NICOX, S.A. (FR) | 2014-09-30 | — | — | US | disclosed |
| US-20120232025-A1 | SAFENER DRUG COMBINATIONS FOR USE WITH NMDA ANTAGONIST DRUGS | OLNEY JOHN W (US) | 2012-09-13 | — | — | US | disclosed |
| WO-1998017306-A1 | METHOD FOR INCREASING BLOOD INSULIN LEVELS IN MAMMALS | ERGO RESEARCH CORPORATION (US) | 1998-04-30 | — | — | WO | disclosed |
| WO-1997041873-A9 | METHOD AND COMPOSITION FOR THE TREATMENT OF LIPID AND GLUCOSE METABOLISM DISORDERS | — | 1998-02-12 | — | — | WO | disclosed |
| WO-1997041873-A1 | METHOD AND COMPOSITION FOR THE TREATMENT OF LIPID AND GLUCOSE METABOLISM DISORDERS | ERGO RESEARCH CORPORATION (US) | 1997-11-13 | — | — | WO | disclosed |
| WO-1997031945-A1 | DNA ENCODING A HUMAN IMIDAZOLINE RECEPTOR | THE UNIVERSITY OF MISSISSIPPI MEDICAL CENTER (US) | 1997-09-04 | — | — | WO | disclosed |
| US-5605911-A | NEUROTOXIC SIDE EFFECT INHIBITION | WASHINGTON UNIVERSITY (US) | 1997-02-25 | — | — | US | disclosed |
| US-4883649-A | BINDER FOR A2-ADRENERGIC RECEPTOR SITES | THE UNIVERSITY OF MICHIGAN (US) | 1989-11-28 | — | — | US | disclosed |
| US-4883649-A | BINDER FOR A2-ADRENERGIC RECEPTOR SITES | THE UNIVERSITY OF MICHIGAN (US) | 1989-11-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250177354-A1 | THERAPEUTIC COMBINATIONS, COMPOSITIONS, AND METHODS FOR DESIGNING AND PRODUCING ENTACTOGENIC MINDSTATES | CNR2, CNR1, HTR6 | ADRA2A 629/4885ADRA2B 883/4885ADRA2C 334/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.